Trial Profile
A Randomized, Multicenter, Open-label Phase Ib/II Study of RO5083945 in Combination With Cisplatin and Gemcitabine/Pemetrexed Versus Cisplatin and Gemcitabine/Pemetrexed in Patients With Advanced or Recurrent Non Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Imgatuzumab (Primary) ; Cisplatin; Gemcitabine; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Roche
- 18 Jul 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database
- 27 Jan 2014 Status changed from active, no longer recruiting to completed as reported on ClinicalTrials.gov.
- 27 Jan 2014 Status changed from active, no longer recruiting to completed as reported on ClinicalTrials.gov.